Background: Patients with pediatric leukemia and sickle cell disease are at risk for developing osteonecrosis (ON), a disease that can result in pain, loss of function, and disability. Hip core decompression surgery is an option aimed to prevent femoral head collapse and avoid future arthroplasty.
Objective: Describe functional outcomes and gait quality among a young population with hip ON before and after hip core decompression.
Methods: Study included participants with hip ON secondary to treatment for hematologic malignancy or sickle cell disease, between 8 and 29 years old, requiring hip core decompression surgery. At one-year follow-up, 13 participants (9 male, median age 17 years) completed the Functional Mobility Assessment (FMA), range of motion, and GAITRite testing.
Results: Participants demonstrated improved mobility and endurance on the FMA at 1-year post-operatively compared to pre-operatively, with higher scores for time on the Timed Up and Go (mean FMA score = 2.92 [SD = 1.32] vs. 2.07 [SD = 1.70]), time on the Timed Up and Down Stairs (3.69 [0.85] vs. 2.92 [1.66]), and 9-Minute Walk Test scores for distance walked (2.69 [0.63] vs. 2.23 [0.93]) and heart rate (4.54 [0.66] vs. 3.31 [1.38]). GAITRite analysis also showed improvements in many gait parameters at one-year follow-up.
Limitations: Cancer treatment complications other than ON could have contributed to results, not all eligible participants agreed to participate, and follow-up was only one year.
Conclusions: Young patients with hip ON demonstrated improvements in functional mobility, endurance, and gait quality one year following hip core decompression.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979580 | PMC |
http://dx.doi.org/10.1097/01.reo.0000000000000306 | DOI Listing |
J Orthop Surg Res
January 2025
Department of Orthopaedics and Traumatology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Turkey.
Background: Avascular necrosis (AVN) of the femoral head is a degenerative condition characterized by ischemic bone death, resulting in pain and impaired mobility. Core decompression, a surgical intervention, is widely performed for stage II AVN to alleviate symptoms and delay disease progression. While clinical and radiological outcomes are well-documented, the psychosocial dimensions of recovery remain underexplored.
View Article and Find Full Text PDFFront Surg
January 2025
The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Baiyun, China.
Background: There are few literatures comprehensively analyzed the global research in hip prosthesis joint infections (HPJI). We aim to clarify the global research trends and analysis the top 10 cited articles in the HPJI field.
Methods: We identified the core collection of articles/reviews in the HPJI field from 2001 to 2021 through the Web of Science Core Collection (WOSCC).
Front Pharmacol
January 2025
Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Background: The debate continues on whether combining core decompression (CD) with regenerative therapy provides a more effective treatment for early femoral head necrosis than CD alone. This systematic review and meta-analysis endeavored to assess its efficacy.
Methods: We systematically searched PubMed, Web of Science, and Cochrane Library through July 2024 for RCTs and cohort studies evaluating the impact of core decompression (CD) with regenerative therapy versus CD alone in early-stage osteonecrosis (ARCO I, II or IIIa or Ficat I or II) of the femoral head (ONFH).
J Hip Preserv Surg
December 2024
Department of Orthopaedics, All India Institute of Medical Sciences, Rishikesh, Dehradun 249203, India.
Osteonecrosis of femoral head (ONFH) can be a debilitating disease, for which numerous salvage surgeries have been popularized to halt its progression. The aim of this study was to assess the clinical and radiological outcomes of a single-incision core decompression (CD) technique using trochanteric autograft in ONFH and to determine the prognostic factors of treatment success. Sixty-six hips (41 patients) of Association Research Circulation (ARCO) 1 and 2 ONFH undergoing CD were included in the study with a mean follow-up of 58 months.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!